Pet scan - OmicsDI

Show results for

Unknown (1432)
Transcriptomics (148)
Genomics (34)
Clinical (34)
Proteomics (33)
Metabolomics (14)
Genomic (2)

Organisms

Homo sapiens (64)
Mycobacterium tuberculosis SP7 (31)
Mycobacterium tuberculosis SP10 (31)
Mycobacterium tuberculosis SP13 (31)
Mycobacterium tuberculosis SP22 (31)
Chlamydomonas reinhardtii (31)
Enterococcus mundtii CRL35 (31)
Oncorhynchus tshawytscha (31)
Mus musculus (27)
Saccharomyces cerevisiae (15)
Drosophila melanogaster (11)
Ciona intestinalis (9)
Corynebacterium glutamicum (5)
Caenorhabditis elegans (5)
Geobacter sulfurreducens PCA (3)
Schizosaccharomyces pombe (3)
Salmonella enterica subsp. enterica serovar Typhimurium str. SL1344 (3)
Solanum lycopersicum (2)
Escherichia coli str. K-12 substr. MG1655 (2)
Candida albicans (2)
Rattus norvegicus (2)
Danio rerio (2)
Arabidopsis thaliana (2)
Acropora formosa (1)
Saccharomyces cerevisiae SK1 (1)
Folsomia candida (1)
Xenopus laevis (1)
Salmonella enterica subsp. enterica serovar Typhimurium (1)
Mycobacterium tuberculosis H37Rv (1)
Escherichia coli K-12 (1)

Organisms

Homo sapiens (10)

Repository

biostudies-arrayexpress (152)
pride (31)
MetaboLights (14)
EGA (13)
ENA (13)
geo (5)
dbGaP (2)
MassIVE (1)

Tissue

Brain (4)
Epithelial cell (3)
Kidney (2)
Cell culture (2)
Digestive gland (1)
Rectum (1)
Gastric juice (1)
Muscle cell (1)
Skeletal muscle fiber (1)
Skin mucus (1)
Fruit (1)
Peritoneal dialysis fluid (1)
Mycelium (1)
Epithelial cell of lung (1)
Microglial cell (1)
Bone marrow (1)
Neuron (1)
Cardiac muscle cell (1)
Macrophage (1)
Heart (1)
Bronchoalveolar lavage (1)
Fibroblast (1)
Primary cell (1)
Erythrocyte (1)
Lung (1)
Liver (1)
Blood cell (1)

Disease

Colorectal Neoplasms (14)
Neoplasm Metastasis (2)
Neoplasms (2)
Alzheimer's disease (2)
Phyllodes tumor (1)
Adenocarcinoma (1)
Colon and gastric cancer patients (1)
Patient suffering from colorectal or pancreatic adenocarcinoma. (1)
Colorectal cancer liver metastases (CRLM) (1)
Liver metastases (1)
1. Secondary hepatic metastases from colorectal cancer2. Hepatocellular carcinoma (1)
Cancer-Bowel-Back passage (rectum) or large bowel (colon) (1)
Carcinoid Tumor (1)
Colorectal Liver Metastases (1)
Pancreatic cancer (1)
Metastatic colorecal adenocarcinoma, K-RAS and N-RAS wild type (1)
Breast cancer (1)
Anal Cancer (1)
Colon cancer (1)
Cholangiocarcinoma (1)
Carcinoma (1)
Colorectal cancer (1)
Myofibrillar myopathy 1 (1)
Cardiomyopathy (1)
Idiopathic pulmonary fibrosis (1)
Rectum cancer (1)
Stroke (1)
Frontotemporal dementia (1)
Non-small cell lung carcinoma (1)
Influenza (1)

Technology Type

Mass Spectrometry (31)
Shotgun proteomics (18)
Mass spectrometry (7)
Mass spectrometry assay (7)
Bottom-up proteomics (4)
Data-dependent acquisition (3)
Top-down proteomics (3)
SWATH MS (2)
Data-independent acquisition (2)
Illumina MiSeq, Illumina HiSeq 2500, ILLUMINA (1)
MSE (1)
Affinity purification coupled with mass spectrometry proteomics (1)
Chemical cross-linking coupled with mass spectrometry proteomics (1)

Instrument Platform

NextSeq 500 (5)
Liquid Chromatography MS - positive - hilic (5)
Liquid Chromatography MS - negative - hilic (4)
Liquid Chromatography MS - alternating - hilic (3)
NextSeq 2000 (2)
NextSeq 550 (2)
Illumina NovaSeq 6000 (2)
Liquid Chromatography MS - positive - reverse-phase (2)
Liquid Chromatography MS - negative - reverse-phase (2)
Liquid Chromatography MS - negative - reverse phase (2)
Agilent DNA Microarray Scanner Model #G2565BA (1)
GenePix 4000B [Axon Instruments] (1)
Orbitrap Fusion Lumos (1)
Liquid Chromatography MS - positive - direct infusion (1)
Liquid Chromatography MS - negative - direct infusion (1)
Gas Chromatography MS - (1)
Gas Chromatography MS - positive (1)
Liquid Chromatography MS - negative (1)
Liquid Chromatography MS - positive (1)
Liquid Chromatography MS - (1)
Exactive (Thermo Scientific) (1)
Liquid Chromatography MS - positive - reverse phase (1)

Publication Date

2010 (48)
2012 (17)
2025 (14)
2014 (14)
2013 (14)
2026 (12)
2015 (11)
2011 (11)
2022 (11)
2016 (8)
2009 (8)
2008 (8)
2024 (6)
2019 (4)
2020 (4)
2017 (3)
2023 (3)
2018 (2)
2006 (2)
2021 (2)
2007 (1)

CHEBI ID

CHEBI:16199 (3)
CHEBI:18089 (3)
CHEBI:7916 (3)
CHEBI:16958 (3)
CHEBI:17596 (3)
CHEBI:17568 (3)
CHEBI:17154 (3)
CHEBI:16919 (3)
CHEBI:16750 (3)
CHEBI:16737 (3)
CHEBI:16335 (3)
CHEBI:9907 (2)
CHEBI:43580 (2)
CHEBI:42111 (2)
CHEBI:27997 (2)
CHEBI:35704 (2)
CHEBI:70959 (2)
CHEBI:32365 (2)
CHEBI:55484 (2)
CHEBI:18183 (2)
CHEBI:17115 (2)
CHEBI:16856 (2)
CHEBI:17490 (2)
CHEBI:57589 (2)
CHEBI:16020 (2)
CHEBI:133086 (2)
CHEBI:73722 (2)
CHEBI:76308 (2)
CHEBI:68441 (2)
CHEBI:20067 (2)

Metabolite Name

Hippuric acid (6)
Taurine (6)
Deoxycytidine (6)
Inosine (6)
Glutathione (5)
Citrulline (5)
Uracil (5)
Niacinamide (5)
Creatine (5)
Creatinine (5)
Pyridoxine (5)
Allantoin (5)
Choline (5)
Tetradecanedioic acid (5)
Riboflavin (5)
Pantothenic acid (5)
Citric acid (5)
Uric acid (5)
Xanthine (5)
Guanosine (5)
Proline betaine (4)
Diethanolamine (4)
N-Isovaleroylglycine (4)
Dimethylglycine (4)
Phytosphingosine (4)
Methionine (4)
Sphingosine 1-phosphate (4)
L-Norleucine (4)
Cytosine (4)
Mesalazine (4)

First Public Date

2024 (5)
2020 (3)
2018 (2)
2022 (1)
2019 (1)
2017 (1)

Study status

Completed (11)
Recruiting (9)
Ongoing (3)
Terminated (3)
Withdrawn (3)
Active, not recruiting (2)
Not provided (2)
Not yet recruiting (1)

Study type

ChIP-chip by tiling array (63)
Transcription profiling by array (40)
Interventional (28)
ChIP-chip by array (9)
ChIP-seq (7)
Unknown experiment type (6)
Other (6)
Observational (6)
ATAC-seq (5)
RNA-seq of coding RNA (4)
Transcription profiling by tiling array (3)
Comparative genomic hybridization by array (3)
Methylation profiling by array (2)
One-color microarray (1)
Proteomic profiling by mass spectrometer (1)
Hi-C (1)
MicroRNA profiling by array (1)

Release Date

2023 (198)
2022 (187)
2021 (162)
2024 (152)
2020 (148)
2025 (139)
2019 (111)
2018 (98)
2017 (62)
2016 (59)
2010 (52)
2015 (48)
2014 (48)
2013 (30)
2012 (30)
2011 (18)
2026 (15)
2009 (13)
2008 (9)
2007 (3)
2006 (2)

Lab affiliation

University of Colorado - Anschutz Medical Campus, Department of Biochemistry and Molecular Genetics, Aurora, CO USA (1)
Department of Radiology Charité - Universitätsmedizin Berlin Charitéplatz 1 10117 Berlin Germany (1)
Turku PET Centre, University of Turku, Turku, Finland Department of Endocrinology, Turku University Hospital, Turku, Finland (1)
Bowel Cancer and Biomarker Lab Kolling Institute The University of Sydney (1)
LMU - Gene Centre Feodor-Lynen-Straße 25 81377 München Germany (1)
Analytical Research Center for Organic and Biological Molecules, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China (1)
Department of Biology and Technology, Kunming University, Kunming, China (1)
Department of immunology, Peking Union Medical College, Beijing, China (1)
Novo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark (1)
Pharmaceutical Sciences - TTB Roche Pharma Research and Early Development Roche Innovation Center Basel F. Hoffmann-La Roche Ltd Building/Room 93/4.44 Grenzacherstrasse 124 CH-4070 Basel, Switzerland (1)
Robert Koch-Institute, Centre for Biological Threats and Special Pathogens, Proteomics and Spectroscopy (ZBS6), Berlin, Germany (1)
School of Life Sciences, The Chinese University of Hong Kong, Sha Tin, N.T., Hong Kong; State Key Laboratory of Agrobiotechnology, and School of Life Sciences, The Chinese University of Hong Kong, Shatin N.T., Hong Kong (1)
Arkana Laboratories, Little Rock, Arkansas, USA (1)
South China Botentical Garden, Chinese Academy of sciences (1)
Centre for Haemato-oncology, Barts Cancer Institute, Queen Mary University of London, London, EC1M6BQ, UK (1)
Institute of Virology, Technical University of Munich, Munich, Germany. (1)
Zhejiang University School of Medicine (1)
ProteoToul, Institute of Pharmacology and Structural Biology (IPBS), CNRS, Toulouse (1)
Pathology and Microbiology Department, University of Nebraska Medical Center, Omaha, NE, USA (1)
Emmy-Noether Research Group Cellular Proteomics and Metabolic Signaling Institute for Diabetes and Obesity Helmholtz Diabetes Center Germany (1)
Amphibian Evolution Lab Pleinlaan 2. 1050 Brussels Belgium (1)
University of Tennessee, Health Science Center, Department of Pediatrics (1)
DZNE Munich, Neuroproteomics, Feodor-Lynen Str. 17, 81377 Munich, Germany (1)
Arkana Laboratories, 10810 Executive Center Drive, Little Rock, Arkansas 72211 (1)
Medizinisches Proteom-Center, Medical Faculty, Ruhr-University Bochum, 44801 Bochum, Germany (1)
Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA (1)
Centre for Proteome Research, University of Liverpool (1)
National Key Laboratory of Medical Molecular Biology & Department of Immunology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (1)
Proteomics program, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark (1)
Shandong Agricultural University (1)

Location

Netherlands (9)
United States (7)
Australia (6)
France (3)
Belgium (2)
Hong Kong (1)
Egypt (1)
Singapore (1)
China (1)
Germany (1)
Italy (1)
United Kingdom (1)

Keyword

FDG-PET-CT (1)
MRS, (1)
Colorectal cancer with histologically proven distant metastases (1)
Advanced chemorefractory colorectal cancer (1)
FDG-PET (1)
Early metabolic response (1)
[18F]PSMA-1007 (1)
18F-Fluciclatide (1)
Radionuclide Imaging (1)
Cetuximab (1)
Identifying an early indicator of drug efficacy (1)
Immunohistochemistry, (1)
Monoclonal antibodies, (1)
Predictive model, (1)
Antiangiogenic agents, (1)
Medical imaging (1)
Colorectal cancer with liver metastases (1)
Fluoroazomycin arabinoside (1)
Carcinoid Tumors (1)
Pulmonary metstasectomy (1)
Telbivudine (1)
FLT-PET (1)
Proliferation markers (1)
68GaNOTA-Anti-HER2 VHH1 (1)
Colorectal Cancer; (1)
Liver; (1)
Metastases; (1)
Resection; (1)
Fluorodeoxyglucose; (1)
Tomography; (1)

Previous page
1 / 170
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 170
Next page

Sort by:

Relevance

Page size

Improving global feature detectabilities through scan range splitting for untargeted metabolomics by high-performance liquid chromatography-Orbitrap mass spectrometry

Untargeted metabolomics aims at obtaining quantitative information on the highest possible number of low-molecular biomolecules present in a biological sample. Rather small changes in mass spectrometric spectrum acquisition parameters may have a significant influence on the detectabilities of metabo...

2016-06-09 | MTBLS233 | MetaboLights

Kinetic models for estimating occupancy from single-scan PET displacement studies.

Not available

S-EPMC10414003 | biostudies-literature

Family members' perspectives on learning cognitively unimpaired older adults' amyloid-β PET scan results.

Not available

S-EPMC8595546 | biostudies-literature

Effects of dynamic [¹⁸F]NaF PET scan duration on kinetic uptake parameters in the knee.

Not available

S-EPMC11440834 | biostudies-literature

Automatic calculation of myocardial external efficiency using a single ¹¹C-acetate PET scan.

Not available

S-EPMC6280778 | biostudies-literature

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Not available

S-EPMC4961236 | biostudies-literature

Feasibility of shortening scan duration of <sup>18</sup>F-FDG myocardial metabolism imaging using a total-body PET/CT scanner.

Not available

S-EPMC11467154 | biostudies-literature

Data on the impact of scan quality on the diagnostic performance of CCTA, SPECT, and PET for diagnosing myocardial ischemia defined by fractional flow reserve on a per vessel level.

Not available

S-EPMC6820078 | biostudies-literature

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.

Not available

S-EPMC7018056 | biostudies-literature

PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment

The purpose of this study is to test whether an early metabolic response, measured by PET/CT scan after the first cycle of chemotherapy, is able to predict which patients with advanced CRC have a better prognosis.

2203395 | ecrin-mdr-crc

Previous page
1 / 170
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 170
Next page

Sort by:

Relevance

Page size

1697 Results

Show results for

Organisms

Organisms

Repository

Tissue

Disease

Technology Type

Instrument Platform

Publication Date

CHEBI ID

Metabolite Name

First Public Date

Study status

Study type

Release Date

Lab affiliation

Location

Tags

Keyword

OmicsDI is part of the ELIXIR infrastructure

Tweets